ResearcherHarvard UniversityActive in the last 2 years
Kunal Jajoo
Matched on OpenAlex author ID A5042498880. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 38
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 8
- Pancreatic Cancer Risk in Patients With Low-Risk Cystic Lesions. Co-author DOI 10.1001/jamanetworkopen.2026.13808↗
- Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
- A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
- What Can We Learn About Pancreatic Adenocarcinoma from Imaging? Last author DOI 10.1016/j.hoc.2022.06.003↗
- Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
- Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
- Screening for Pancreatic Cancer in High-risk Populations. First author DOI 10.1016/j.gtc.2015.10.001↗
- Imaging and Endoscopic Approaches to Pancreatic Cancer. Last author DOI 10.1016/j.hoc.2015.04.008↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ana Babić · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Andrea J. Bullock · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Ehsan Irajizad · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Thomas E. Clancy · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Kimmie Ng · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Michael D. Kluger · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Johannes Francois Fahrmann · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Brian Matthew Wolpin · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Samir Hanash · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Anirban Maitra · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- John A. Chabot · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Jeanine M. Genkinger · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Fay Kastrinos · 3 shared papers, 2021–2024 · strength 0.35
- Paper Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. DOI 10.1136/gutjnl-2023-331074↗
- Paper A blood-based metabolomic signature predictive of risk for pancreatic cancer. DOI 10.1016/j.xcrm.2023.101194↗
- Paper Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. DOI 10.1053/j.gastro.2020.11.052↗
- Michael Hayden Rosenthal · 2 shared papers, 2015–2022 · strength 0.31
- Arya Haj Mirzaian · 1 shared paper, 2026 · strength 0.30
- Ramin Khorasani · 1 shared paper, 2026 · strength 0.30
- Avinash R. Kambadakone · 1 shared paper, 2026 · strength 0.30
- Yasmin Genevieve Hernandez-Barco · 1 shared paper, 2026 · strength 0.30
- Khoschy Schawkat · 1 shared paper, 2022 · strength 0.22
- Jody V. Vykoukal · 2 shared papers, 2021–2023 · strength 0.22
- Chen Yuan · 1 shared paper, 2024 · strength 0.13
- Jacob Edward Till · 1 shared paper, 2024 · strength 0.13
- Roni Ben‐Ami · 1 shared paper, 2024 · strength 0.13
- Douglas Adam Rubinson · 1 shared paper, 2024 · strength 0.13
- Qiao-Li Wang · 1 shared paper, 2024 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.